Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio vs Platelet-to-lymphocyte ratio

Abstract

Although elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been reported to be inverse prognostic predictors of survival in patients with pancreatic cancer (PC), the comparison of their prognostic roles in patients with PC undergoing gemcitabine-based chemotherapy and 5-fluorouracil (5-FU) remains unclear. This study was designed and performed to determine the predictive roles of NLR and PLR in patients diagnosed with PC who underwent one of these two regimens. We retrospectively enrolled 95 patients diagnosed with PC undergoing supportive care, gemcitabine-based chemotherapy or 5-FU therapy from January 2015 to October 2018. Univariate and multivariate Cox regression analyses were done to identify clinicopathological predictors of time to treatment failure (TTF) and overall survival (OS), including pretreatment NLR and PLR. The statistical data showed that pretreatment NLR was significantly associated with metastasis. Among all analyzed variables, pretreatment NLR was an independent prognostic predictor of both TTF and OS of patients with PC, with NLR>4.0 predicting worse survival. PLR, however, didn't independently predict TTF or OS. There were no significant difference in the OS of patients undergoing gemcitabine-based regimens and 5-FU regimens when divided into two subgroups: NLR ≤4.0 and >4.0. In conclusion, pretreatment NLR is a promising independent outcome predictor for patients with PC, while NLR might not be a suitable factor in the selection of regimens for patients with PC.

Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel

“…Selecting the appropriate patient for GnP chemotherapy is necessary. The CA19-9 [ 9 ], the serum albumin level [ 10 ], older age [ 10 ] and the neutrophil-to-lymphocyte ratio [ 11 ] have been reported as predictive and pretreatment markers of GnP chemotherapy for patients with UR-MPC. However, the association between venous thromboembolism (VTE) and the prognosis of patients receiving GnP chemotherapy has not been fully established.…”

Interleukin-25 as a Potential Biomarker in Lung Metastasis of Hepatocellular Carcinoma with HBV History in Chinese Patients: A Single Center, Case-control Study

“…The baseline data was taken within one week before treatment. Tumor location and TNM (tumor, lymph node and metastasis) staging were judged from the results of CT or MRI in accordance with the 7th edition of the AJCC Cancer Staging Manual 21 . AST, ALT, GGT and TBA were included in serological detection.…”

Value of markers of systemic inflammation for the prediction of postoperative progression in patients with pancreatic neuroendocrine tumors

“…Systemic inflammation may be evaluated by the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and platelet to white blood cell ratio (PWR), the assessments of which are simple, non-invasive, and low cost. Such ratios not only have predictive value in solid cancers but also are prognostic biomarkers for many malignancies, such as renal cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer (9)(10)(11)(12)(13). The above indexes are routinely measured; therefore, their clinical application value has gradually increased in recent years.…”